In the past decade, significant insights into host and tumor factors promoting oncogenesis and treatment resistance have led to the development of innovative cancer therapies. These include novel antibody-drug conjugates, chimeric antigen receptor T-cell (CAR-T) therapies, and bispecific T-cell engagers. Emerging research also highlights the microbiome’s role as both a biomarker and a modulator of anti-tumor responses. The field is moving toward personalized treatments tailored to individual patient profiles. This commentary explores these emerging therapies’ basic concepts, promises, and challenges.

Advanced technologies now target specific tumor pathways, leading to more effective and less toxic treatments. Novel delivery mechanisms, such as engineered antibodies and CAR-T therapies, have shown remarkable efficacy in hematological malignancies and are being adapted for solid tumors. Additionally, the microbiome’s modulation is gaining traction as an adjunct therapy to enhance treatment efficacy and reduce toxicity. This paper discusses these advancements and their potential to revolutionize cancer therapy.

Reference: Capella MP, Esfahani K. A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine. Curr Oncol. 2024;31(4):1913-1919. doi: 10.3390/curroncol31040143.